Brief: XBiotech Inc Plans To Seek FDA Guidance Based On Phase III Studies In Oncology Findings
Brief: Xbiotech Announces Dismissal Of Securities Class Action Suit
Brief: Xbiotech Completes Enrollment In Phase 2 Multicenter Study For Bermekimab
Brief: XBiotech Announces European Patent For Treatment Of Inflammatory Skin Diseases
U.S. STOCKS ON THE MOVE-Tilray, U.S. homebuilders, GNC Holdings, Fred's, Pivotal Software
U.S. STOCKS ON THE MOVE-WageWorks, Pivotal Software, Tailored Brands, Fred's, Kroger
U.S. STOCKS ON THE MOVE-Kroger, Xbiotech, Impinj, Acorda Therapeutics
XBiotech: Jumps after positive interim results for dermatitis treatment
Brief: Xbiotech Announces Completion And Positive Interim Findings For Initial Cohort In Bermekimab Pilot Study In Atopic Dermatitis
XBiotech: Adds noted cardiologist to its scientific advisory board
Brief: XBiotech Announces First Patient In Phase 2 Study Evaluating Subcutaneous MABp1 In Patients With Hidradenitis Suppurativa
Brief: Xbiotech Announces First Patient In Phase 2 Study Evaluating Subcutaneous MABP1 In Patients With Hidradenitis Suppurativa
Brief: XBiotech Announces First Patient In Phase 2 Study Evaluating Patients With Atopic Dermatitis
Brief: XBiotech Announces Upcoming Phase 2 Clinical Studies In Dermatology
Brief: Xbiotech Announces Upcoming Phase 2 Clinical Studies In Dermatology
Brief: XBiotech In-Licenses Anti-NY-ESO 1 Antibody Targeting Advanced Cancer
Brief: XBIOTECH ENROLLS FIRST PATIENT IN STUDY EVALUATING MABP1 IN WITH ONIVYDE
Brief: XBiotech announces agreement with Cedars-Sinai Medical Center to evaluate MABP1 combination for the treatment of pancreatic cancer
Brief: XBiotech - European Medicines Agency maintains its May 18, 2017 opinion